Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Grove Bank & Trust

Grove Bank & Trust boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1,783.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 810 shares of the biopharmaceutical company's stock after acquiring an additional 767 shares during the period. Grove Bank & Trust's holdings in Regeneron Pharmaceuticals were worth $514,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Pamalican Asset Management Ltd purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $4,915,000. Intact Investment Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $356,000. Rhenman & Partners Asset Management AB grew its holdings in shares of Regeneron Pharmaceuticals by 11.4% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock worth $30,956,000 after buying an additional 4,457 shares in the last quarter. Fagan Associates Inc. raised its position in shares of Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock valued at $9,205,000 after buying an additional 3,832 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after buying an additional 814,713 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 0.9%

NASDAQ:REGN traded up $4.72 on Wednesday, reaching $513.58. The stock had a trading volume of 841,026 shares, compared to its average volume of 882,745. The company has a 50-day moving average of $561.15 and a 200 day moving average of $645.97. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The stock has a market cap of $55.45 billion, a P/E ratio of 13.07, a price-to-earnings-growth ratio of 1.91 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The firm's quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter last year, the firm posted $9.55 EPS. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.69%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Analyst Ratings Changes

Several research firms have commented on REGN. Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. The Goldman Sachs Group lowered their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Morgan Stanley reduced their target price on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating on the stock in a research report on Monday, June 2nd. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Finally, Robert W. Baird dropped their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $836.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.